Abstract
α1-antitrypsin deficiency is a genetic disorder which contributes to the development of chronic obstructive pulmonary disease, bronchiectasis, liver cirrhosis and panniculitis. The discovery of α1-antitrypsin and its function as an antiprotease led to the protease-antiprotease hypothesis, which goes some way to explaining the pathogenesis of emphysema. This article will review the clinical features of α1-antitrypsin deficiency, the genetic mutations known to cause it, and how they do so at a molecular level. Specific treatments for the disorder based on this knowledge will be reviewed, including α1-antitrypsin replacement, gene therapy and possible future therapies, such as those based on stem cells.
| Original language | English |
|---|---|
| Pages (from-to) | 481-492 |
| Number of pages | 12 |
| Journal | Respiration |
| Volume | 74 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1 Aug 2007 |
Keywords
- biological therapy
- epidemiology, molecular
- genetics, population
- molecular biology
- alpha 1-antitrypsin deficiency
Fingerprint
Dive into the research topics of 'Alpha one antitrypsin deficiency: From gene to treatment'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver